Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

One To Watch: Chi-Med Approaches Inflection Points

Executive Summary

Hutchison China MediTech, or Chi-Med, will report pivotal or proof of concept data for savolitinib, fruquintinib and two other tyrosine kinase inhibitor candidates by Q1 2017. Having built a global cancer and inflammation R&D pipeline on the back of what started out 16 years ago as a domestic commercial botanicals business based in China, Chi-Med is now one to watch.

Advertisement

Related Content

PROFILE: Chi-Med Lays Out Broad Strategy As Fruquintinib Advances

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register